Resverlogix Corp.


Resverlogix in Recent News

Donald McCaffrey, President & CEO on BNN’s Business Day, April 22, 2015

April 27, 2015- BioCentury: Hepalink gains rights to Resverlogix’s RVX-208 in China. Link here:

April 28, 2015- BioWorld Today: Phase III Starting Soon. Resverlogix getting specific: With potential $400M BET, Hepalink licensing accord, by Randy Osborne. Link here to access the full article.

April 28, 2015- Bloomberg Business: Resverlogix in Discussions to Be Bought, by Eric Lam. Link here:

April 28, 2015- BioSpace Breaking News: Resverlogix (RVX.TO) CEO Says It’s in Talks With Suitors, After $100M in Q1 Deals, by Riley McDermid. Link here:

April 28, 2015- Fierce Biotech: Resverlogix gets a $116M China Drug development deal, stokes buyout buzz, by John Carroll. Link here:

April 28, 2015 - GEN News Highlights: Hepalink Buys China-Area Rights to Resverlogix's CV Candidate for Up-to-$441.5M Link here:


Resverlogix presented at The 17th Annual BIO CEO & Investor Conference 2015 on Monday, February 9, 2015. The archived replay will be available for a period of 90 days following the event. 

Click here to access the archived webcast:

Events - April to June 2015

Resverlogix will be attending several key industry conferences. Not all events offer a presentation opportunity. Please note this list is not exhaustive and subject to change.

China BIO Partnering Forum 2015, Shanghai, China, April 15-16.

BioNetwork East 2015, Miami, Florida, May 4-6.

ATVB (Atherosclerosis, Thrombosis, and Vascular Biology) 2015, San Francisco, CA, May 7-9.

ISA (International Atherosclerosis Society) 2015, Amsterdam, Netherlands, May 23-26.  

ICNT 2015 – 17th International Conference on Nephrology and Therapeutics, London, England, May 25-26.

ERA-EDTA (European Renal Association – European Dialysis Transplant Association) 2015, London, England, May 28-31. 

ADA (American Diabetes Association) 2015, Boston, MA, June 5-9.

BIO International Convention 2015, Philadelphia, PA, June 15-18.

15th European Meeting on Complement in Human Disease, Uppsala, Sweden, June 27-30.

To arrange a meeting with senior management, please contact Sarah Zapotichny, Director of Investor Relations at